Você procurou por: papillary dermis (Inglês - Dinamarquês )

papillary
papillær-

papillary erosion
erosio papillaris

dermis of skin disc
dermis af hudlap

serous papillary cystadenoma
serøst papillifert cystadenom

raphe-papillary transversale
raphe-papiltransversal

necrosis in the dermis was rarely observed.
nekrose i dermis blev sjældent observeret.

us may show remediable complications (vsd,papillary rupture, aneurysm, etc.).
ulkan vise helbredelige komplikationer (ventrikelseptum defekt, papillær ruptur, aneurisme osv.).

the dying keratinocytes release mediators that begin the inflammatory cascade which acts on the cells in the dermis, particularly the stromal and endothelial cells.
de døende keratinocytter frigiver mediatorer, der starter den inflammatoriske kaskade, der påvirker cellerne i dermis, navnlig de stromale og endotele celler.

the histopathological evaluation indicates slight acanthosis, practically without any dermal papillary inflammation - the only change considered si gni ficant.
den histopatologiske vurdering viste svag akantose, praktisk talt uden papi hær hudinflammation, som den eneste signifikante ændring.

there was also an increase in renal infarcts and papillary necrosis in female rats at exposures 7 and 10-fold compared to humans given 1250 mg of lapatinib once daily.
der er også set en forøgelse af nyreinfarkt og papillær nekrose hos hunrotter ved eksponeringer, der var 7-10 gange større sammenlignet med mennesker, som fik 1250 mg lapatinib en gang daglig.

destruction of sebaceous cells, focal epidermal necrosis with a transient acute inflammation and diffuse reactive changes in the keratinocytes as well as transient secondary oedema and inflammation of dermis are observed.
der er observeret ødelæggelse af talgkirtelceller, fokal epidermal nekrose med en forbigående akut inflammation og diffuse reaktive ændringer i keratinocytter samt forbigående sekundært ødem og inflammation i dermis.

papillary thyroid cancer: ema.europa.eu/find medicine/human medicines/rare disease designation.
papillær thyroideacancer: ema.europa.eu/find medicine/human medicines/rare disease designation.

in some cases, the skin may be fractionated into the exposed area of skin and area of skin under the cell flange, and into stratum corneum, epidermis and dermis fractions, for separate analysis.
i nogle tilfælde kan huden opdeles i det eksponerede hudareal og hudarealet under celleflangen, samt i fraktioner bestående af stratum corneum, epidermis og dermis, som analyseres hver for sig.

after 24 hours, the mean cumulative absorption (including accumulation in the dermis) through human skin was 0.2% of the administered dose.
efter 24 timer var den gennemsnitlige kumulative absorption (inklusive akkumulation i huden) gennem human hud 0,2 % af den anvendte dosis.

typical undesirable side-effects associated with nsaids have been seen, such as lesions in the alimentary tract or in the kidneys, soft faeces, urticaria, lethargy and renal papillary necrosis.
typiske uønskede bivirkninger forbundet med nsaid, såsom læsioner i fordøjelseskanalen eller i nyrerne, blød afføring, nældefeber, apati samt renal papillær nekrose er set.

histologically, 66.1% had a confirmed diagnosis of papillary thyroid cancer and 33.9% had follicular thyroid cancer which included hürthle cell 14.8% and clear cell 3.8%.
histologisk havde 66,1 % en bekræftet diagnose på papillær tyreoideacancer, og 33,9 % havde follikulær tyreoideacancer, som omfattede hürthle-celle 14,8 % og clear-celle 3,8 %.